Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Enhanced predictive validity of integrative models for refractory hyperthyroidism considering baseline and early therapy characteristics: a prospective cohort study

Fig. 3

Distribution of patients by 3-month cumulative MMI dosage. MMI methimazole. *P < 0.05. High: 3-month cumulative MMI dosage ≥ 1730 mg. Medium: 3-month cumulative MMI dosage 1350–1730 mg, excludes 1730 mg. Low: 3-month cumulative MMI dosage < 1350 mg

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us